长效眼内氟轻松植入物治疗黑色素瘤相关视网膜病变一例:三年随访
本文报告一例73岁女性黑色素瘤相关视网膜病变(MAR)患者,未接受全身免疫抑制,仅予双侧玻璃体内氟轻松缓释植入物治疗。治疗后一周视力改善,视野与ERG部分恢复,三年随访视力稳定且全身疾病缓解,但出现双侧白内障并行手术。作者认为缓释眼内激素植入物可能为MAR提供替代全身免疫抑制的有效安全选择,但单例结果需谨慎推广。
要点
- MAR患者未用全身免疫抑制,仅玻璃体内氟轻松植入后视功能改善并稳定三年。
- 治疗一周内双眼视力从20/30(OD)和20/16(OS)改善至20/20。
- 约两年后出现双侧白内障,白内障手术顺利,三年时视力维持20/20。
核心结论
- 玻璃体内缓释氟轻松植入物可改善MAR患者的视觉症状、视野和视网膜功能,可能作为全身免疫抑制的替代方案,但单例结果需谨慎推广。
研究设计与样本
- 本文为单例73岁女性MAR患者的3年随访报告,患者接受双侧玻璃体内氟轻松缓释植入物治疗,未使用全身免疫抑制。
主要发现
- 治疗后1周内双眼视力从基线20/30(OD)和20/16(OS)改善至20/20。
- 详细ERG监测显示特征性异常部分缓解,提示内层视网膜ON双极细胞功能改善。
- 注射后约2年出现双侧白内障,白内障手术顺利;治疗后3年视力稳定在20/20(双眼),全身疾病缓解。
关键数值与推荐
- 基线眼底检查、眼底自发荧光和OCT正常,无黄斑囊样水肿证据。
- 自动视野计显示视野缺损,全视野ERG显示与弥漫性ON双极细胞功能障碍一致的发现,符合MAR典型表现。
临床怎么用
- 对于MAR患者,尤其存在全身免疫抑制禁忌时,可考虑玻璃体内缓释激素植入物作为治疗选择。
- 治疗期间需监测白内障等眼部并发症,该例在约2年后出现双侧白内障并需手术。
局限性
- 本文为单例病例报告,结果推广需极度谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome in which antiretinal antibodies crossreact with retinal ON-bipolar cells, resulting in night blindness and progressive visual field loss. Current therapeutic options include cytoreductive surgery in combination with immunoglobulin, corticosteroids, or plasmapheresis, but their effectiveness is limited and may be contraindicated, given the possible protective role of circulating autoantibodies against metastatic spread. We report 3-year follow-up of the first case (to our knowledge) of MAR treated with intravitreal long-acting steroid implants. OBJECTIVE: To report on a patient with MAR who was treated with intravitreal fluocinolone acetonide implants in the absence of systemic immunosuppression. DESIGN, SETTING, AND PARTICIPANTS: This is a 3-year follow-up of a 73-year-old woman with a history of surgical excision of a malignant melanoma of the left pinna who presented with visual symptoms of shimmering and nyctalopia. Fundus examination, fundus autofluorescence, and optical coherence tomography were normal, with no evidence of cystoid macular edema. Automated perimetry showed a reduction in visual field and full-field electroretinography (ERG) demonstrated findings consistent with generalized ON-bipolar cell dysfunction, typical of MAR. The patient was treated with bilateral fluocinolone acetonide intravitreal implants. MAIN OUTCOMES AND MEASURES: Visual acuity, visual field, and electroretinography testing for 3 years after treatment. RESULTS: Visual fields improved in this 73-year-old patient from 20/30 (Snellen measured as 6/9) OD and 20/16 (6/5) OS at baseline to 20/20 OU within 1 week of treatment. Detailed electroretinography monitoring indicated characteristic abnormalities that partly resolved after treatment, consistent with improved inner retinal ON-bipolar cell function. Bilateral cataracts developed approximately 2 years after injection; cataract surgery was performed uneventfully. At 3 years posttreatment, the patient remained visually stable and in systemic disease remission, with best-corrected visual acuity remaining at 20/20 OU. CONCLUSIONS AND RELEVANCE: We report what is, to our knowledge, the first case of MAR treated with intravitreal slow-release corticosteroid implants, which shows improvements in visual symptoms, visual fields, and retinal function. Sustained-release intraocular steroid implants may offer an effective and safe alternative to systemic immunosuppression in MAR, although results from 1 case should be generalized with abundant caution.
引用
- Karatsai E, Robson AG, Taylor SRJ, et al. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression. JAMA Ophthalmol. 2019. PMID: 30896772. doi:10.1001/jamaophthalmol.2019.0284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。